CARVEDILOL COMBINED WITH TELMISARTAN IN THE TREATMENT OF ESSENTIAL HYPERTENSION AND ITS EFFECT ON INFLAMMATORY FACTORS AND RENAL FUNCTION OF PATIENTS

Chuan Hao, WeiWang, DongLing Lu, Yao Hu, Xuejun Chen^* 

Department of Medicine, Gui Zhou provincial Orthopaedic Hospital, Guiyang550002, Guizhou Provincial, China

Objective: This study aimed to explore the efficacy of carvedilol combined with telmisartan for essential hypertension (EH) and its effect on inflammatory factors and renal function of patients.

Methods: We randomly assigned 110 EH patients treated in our hospital from March 2018 to May 2019 to receive telmisartan (50 cases, the control group, CG) or to receive carvedilol combined with telmisartan (60 cases, the observation group, OG). The two groups were compared in the clinical efficacy, the levels of inflammatory factors, the levels of markers for renal function, and the incidence of renal injury. Pearson test was used to analyze the correlation between blood pressure and markers for renal function.

Results: The overall response rate was remarkably higher in OG than in CG. After treatment, OG had remarkably lower levels of inflammatory factors, lower levels of markers for renal function, and a remarkably lower incidence of renal injury compared to CG. The blood pressure was positively related to the levels of markers for renal function.

Conclusion: Carvedilol combined with telmisartan in the treatment of EH can significantly reduce the expression of inflammatory factors, improve renal function, and enhance the treatment response rate.